Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp. is set to unveil its Q1 2024 financial results on May 9, with a post-announcement conference call to discuss the outcomes and business developments. The company specializes in non-invasive medical devices for tissue ablation, with TULSA-PRO and Sonalleve among their key products, both having received significant international regulatory approvals.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
